{"id":10913,"date":"2026-10-20T13:22:47","date_gmt":"2026-10-20T17:22:47","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=10913"},"modified":"2026-10-20T13:40:50","modified_gmt":"2026-10-20T17:40:50","slug":"nasdaq-biotech-index-up-big-medicure-will-be-30-within-12-months","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/nasdaq-biotech-index-up-big-medicure-will-be-30-within-12-months\/","title":{"rendered":"NASDAQ Biotech Index Up 2.56%, Medicure Will Be $30+ Within 12 Months"},"content":{"rendered":"\n<div style=\"width:100%; max-width:650px; margin:0 auto; padding:0 10px; box-sizing:border-box; font-family:Tahoma,Geneva,Arial,sans-serif; font-size:14px; line-height:1.6; color:#333333; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; text-size-adjust:100%; mso-line-height-rule:exactly; display:block;\">\n<p style=\"margin:0 0 16px; padding:0; font-size:14px; line-height:1.6;\">The <strong>NASDAQ Biotechnology Index (IBB)<\/strong> is <span style=\"color:#27ae60;\"><strong>up by 2.56%<\/strong><\/span> today and <strong>NIA&#8217;s President<\/strong> is <span style=\"color:#27ae60;\"><strong>continuing to add<\/strong><\/span> to his <strong>Medicure (TSXV: MPH)<\/strong> position. <strong>MPH<\/strong> is the <strong><span style=\"color:#2980b9;\">world&#8217;s<\/span> <span style=\"color:#27ae60;\">#1 most undervalued<\/span> biotech stock<\/strong> and will be <strong>$30+ per share<\/strong> within the next 12 months.<\/p>\n\n<p style=\"margin:0 0 16px; padding:0; font-size:14px; line-height:1.6;\">The <strong>U.S. Food and Drug Administration<\/strong> has granted both <strong>Rare Pediatric Disease Designation<\/strong> and <strong>Orphan Drug Designation<\/strong> to <strong>MC-1<\/strong> for the <span style=\"color:#e74c3c;\"><strong>treatment of seizures associated with PNPO deficiency<\/strong><\/span>. In addition, the <strong>European Medicines Agency<\/strong> has granted <strong>Orphan Drug Designation<\/strong> to <strong>MC-1<\/strong> for the <span style=\"color:#e74c3c;\"><strong>treatment of PNPO deficiency<\/strong><\/span>. <strong>Medicure<\/strong> has also <strong><span style=\"color:#27ae60;\">received<\/span> Fast Track Designation<\/strong> for <strong>MC-1<\/strong> in <span style=\"color:#e74c3c;\"><strong>PNPO deficiency<\/strong><\/span>, which is intended to facilitate the <span style=\"color:#27ae60;\"><strong>development<\/strong><\/span> and <span style=\"color:#27ae60;\"><strong>review<\/strong><\/span> of a future <strong>New Drug Application<\/strong> by the FDA.<\/p>\n\n<p style=\"margin:0 0 16px; padding:0; font-family:Tahoma,Geneva,Arial,sans-serif; font-size:8px; line-height:1.5; color:#333333;\"><em>Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA&#8217;s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The NASDAQ Biotechnology Index (IBB) is up by 2.56% today and NIA&#8217;s President is continuing to add to his Medicure (TSXV: MPH) position. MPH is the world&#8217;s #1 most undervalued biotech stock and will be $30+ per share within the next 12 months. The U.S. Food and Drug Administration has granted both Rare Pediatric Disease [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10914,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,28,414],"class_list":["post-10913","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-etfs","tag-mph"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/10913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=10913"}],"version-history":[{"count":3,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/10913\/revisions"}],"predecessor-version":[{"id":10917,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/10913\/revisions\/10917"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/10914"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=10913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=10913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=10913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}